Background Firefly luciferase (Fluc) has routinely been used to quantitate and analyze gene expression in vitro by measuring the photons emitted after the addition of ATP and luciferin to a test sample. It is now possible to replace luminometer-based analysis of luciferase activity and measure luciferase activity delivered by viral vectors directly in live animals over time using digital imaging techniques.
Introduction
Novel techniques have been developed to image small animals non-invasively and it is now possible to follow protein expression over time in the same animal. One such imaging technique measures bioluminescence from a family of luciferases [1] . Assays utilizing firefly luciferase (Fluc) are routinely used for characterizing gene expression levels in vitro. Recent improvements in optical imaging technology have brought luciferases back to the forefront of biological tools. Advantages of bioluminescence imaging over other light-based systems include little-to-no background luminescence from normal tissue and rapid substrate turnover. Two luciferases derived from the firefly (Photinus pyralis) or the sea pansy (Renilla reniformis) are commonly used, and possess distinctive substrate requirements, which can allow sequential imaging of two processes in the same animal [2] . Based on these substrate differences, this dual imaging technique has been used to simultaneously monitor gene delivery and tumor reduction in cancer gene therapy [3] .
It is now possible to integrate bioluminescence imaging with viral vector-mediated gene delivery to assess the extent of protein expression in real time longitudinally without sacrificing the animal. Of the several viral gene delivery systems that have been developed to study and treat disease states, those useful for post-mitotic cells, such as neurons, include recombinant adenoassociated virus (AAV), adenovirus (Ad), lentivirus (LV), and herpes simplex virus (HSV) [4] . Several groups have previously shown that HSV-amplicon vectors are efficiently delivered into the central nervous system without toxicity, infecting mostly neurons [5] . Compared to other vectors, advantages of HSV-amplicon vectors include a large transgene capacity, up to 150 kb DNA [6] , relatively high titers [10 8 transducing units (t.u.)/ml] [7] , no expression of viral proteins, and broad cell and host range [8] . Using helper-free virus packaging systems [7] , amplicon vectors can be packaged free of contaminating helper virus and thereby have minimal to no toxicity, which is critical for gene delivery into the brain and other sensitive tissues.
A first-generation rapamycin-based promoter system was previously tested in an amplicon vector including both components of the dimerizer system using dsRed as a reporter marker for induction [9] . These studies indicated that, even in the uninduced state, promoter activity from the amplicon vector was detectable. Further, the studies reflected flaws with the original dsRed protein when used as a marker gene, including a delay in protein detection (48 h) and variations in fluorescence intensity. More recently, single retrovirus (RV) vectors have also been designed to include both components of the dimerizer system [10] . However, the RV vectors remain constrained by their relatively small transgene capacity (∼8 kb).
In this study, the dimerizer-regulated amplicon vector was improved to minimize baseline activity and maximize induction. This included incorporating a more potent transactivation cassette and replacing the dsRed marker protein with Fluc to investigate the potential for bioluminescence imaging. In addition, the inducible cassette was flanked with insulator regions from the β-globin gene [11] . The control of gene expression was evaluated in cultured cells by dose-dependent quantitation of bioluminescence and transgene expression was monitored in the brains of live mice over time.
Materials and methods

Plasmid construction
The regulatable amplicon plasmid (pHSv.IGiL(a)) was constructed in several steps. First, an enhanced green fluorescent protein (eGFP)-expressing amplicon plasmid (pHRG4.6) [9] was modified to create unique NdeI, PacI, and AscI cloning sites, and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) [12] was inserted downstream of eGFP (pHRG4.66; details upon request). Then the human cytomegalovirus promoter (CMV)-driven transactivating cassette from pC 4 N 2 -R H S3H/ZF3 (provided by ARIAD Pharmaceuticals, Cambridge, MA, USA) was excised by MluI-XhoI digestion, followed by NheI linker addition. This fragment was then ligated into the NheI site (located immediately downstream of the HSV pac) in pHRG4.66 to create pHRG.C4N2-2. pGL3 (Promega, Madison, WI, USA) was linearized with SmaI, and EcoRI linkers added. The Fluc cDNA was then isolated by EcoRI/XbaI digestion and subcloned into pZ12-I-PL-5 (ARIAD) digested with EcoRI/SpeI to create PL5-Luc3. To insert the inducible cassette into a flanked insulated region, pJC13-1 [11] was modified to remove the mHS2 enhancer (EcoRI deletion) and neomycin resistance gene (BamHI deletion) and the SalI and EcoRI sites changed to AscI sites to create pJC13-3. The inducible cassette containing Fluc was excised and modified by SmaI digest, followed by BamHI linker addition, and subcloned into pJC13-3, such that the cassette was in anti-sense orientation relative to the insulator elements. Two additional HSV amplicon plasmids were constructed, pHRG.luc3 and pHCBAIG(W)luc3, to serve as positive Fluc expression controls (details upon request). pHRG.luc3 expressed Fluc from the CMV promoter and eGFP from the RSV promoter. pHCBAIG(W)luc3 drove expression of a bicistronic cassette (Fluc-IRES-eGFP) from the hybrid CMV enhancer/chicken β-actin promoter (CBA). All plasmid vectors were transformed into STBL4 cells (Invitrogen, Carlsbad, CA, USA) and DNA isolated using either QIAgen Endofree maxi kits (Valencia, CA, USA) or twice-banded using cesium chloride gradient centrifugation. Constructs were verified by restriction digest analysis and sequencing at junction sites. Figure 1 shows the constructs used in these experiments. All reagents were purchased from New England Biolabs (Beverly, MA, USA) unless otherwise indicated.
Cell culture
Monkey Vero2-2 cells (from Dr. Rozanne Sandri-Goldin, University of California, Irvine, CA, USA) and human embryonic kidney 293T/17 cells (from Dr. David Baltimore, Massachusetts Institute of Technology, Cambridge, MA, USA) were cultured in 10% fetal bovine serum (FBS)/10 mM HEPES/Dulbecco's modified Eagle's medium (DMEM), pH 7.6, with and without G418, respectively [13, 14] . Human Gli36 glioma cells (from Dr. Anthony Campagni, UCLA School of Medicine) were maintained as described for 293T/17 cells. All cells were cultured in a water-jacketed incubator maintained with 5% CO 2 /95% O 2 at 37 • C. FBS was purchased from Sigma (St. Louis, MO, USA). All other culture media and reagents were purchased from Invitrogen (Carlsbad, CA, USA).
Amplicon vector production and titration
HSV amplicon vectors were packaged using the BAC helper-free system, as previously described [7] . Concentrated vector stocks were stored in aliquots at −80 • C. Vector titers were determined as eGFP-expressing cells 24 h after infection of 293T/17 cells, and expressed as transducing units (t.u.)/ml. Titers were typically 1 × 10 8 t.u./ml. 
Infection and rapamycin administration in culture
Fluorescence imaging
At various time points after infection, images of eGFPexpressing and Fluc-immunopositive cells were captured on an inverted fluorescent microscope to assess vector transduction. eGFP and rhodamine filters (Chroma, Rockingham, VT, USA) were used to detect and capture images using the MetaVue (Universal Imaging Corp., Downingtown, PA, USA) imaging system on a Nikon Eclipse 2000U. Cells were fixed in 4% paraformaldehyde (PFA; in 0.1 M phosphate buffer, pH 7.4), then stained using standard protocols for Fluc with an antibody against Fluc (Promega; 1 : 100) followed by donkey antigoat-Alexa555 (Molecular Probes, Eugene, OR, USA; 1 : 1000), and for eGFP (Molecular Probes; 1 : 1000) followed by donkey anti-rabbit-Alexa488 (Molecular Probes; 1 : 1000).
Western analysis
Samples were harvested in RIPA buffer and processed using standard methods and protocols [16] . Equal numbers of cells were size-fractionated on 12% acrylamide gels and transferred onto nitrocellulose membranes. The blots were probed and processed for Fluc immunoreactivity as described by the manufacturer (Promega) with a goat anti-luciferase antibody (1 : 1000) followed by rabbit anti-goat-HRP secondary antibody (Sigma) or for β-tubulin using a mouse anti-beta-tubulin antibody (Sigma, 1 : 10 000) followed by anti-mouse-HRP secondary antibody (Sigma, 1 : 1000). Signal was visualized using ECL substrate (Pierce, Rockford, IL, USA). For Fluc densitometry, the blots were scanned and saved as TIFF files, and then imported into PhotoshopCS (Adobe, San Jose, CA, USA) for analysis. Briefly, the image was inverted, such that the bands were white, and then processed to determine the mean intensity of each band.
Luminescence and bioluminescence in culture
Approximately 20 h after induction, cells were harvested in RLB buffer (Promega), freeze-thawed and used to measure luciferase activity on a DYNEX Microtiter plate luminometer (Chantilly, VA, USA). Freshly prepared D-luciferin (Biosynth International, Naperville, IL, USA) was added to each sample for a final concentration of 150 µg/ml. The normalized sums of the photon counts in each well were then calculated. For bioluminescence imaging, live cells were given fresh D-luciferin as described above, and then imaged as described for bioluminescence imaging below. All cell culture experiments were performed in triplicate and repeated at least three times.
Stereotaxic procedure
All animals were maintained according to NIH guidelines. In this representative set of experiments, two groups of male nude mice (N = 5/group; MGH Comparative Core Facility), 4-6 weeks of age, were injected with either HSv.IGiL(a) or HRG.luc3 unilaterally into the cortex. The mice were deeply anesthetized using a cocktail of ketamine/xylazine (25 and 5 mg/ml, respectively, in saline), 0.12 ml/30g body weight. When the mice were insensitive to footpad pinch reflex, the animals were positioned in a Kopf stereotaxic apparatus and burr holes drilled into the skull (+0.22 mm from Bregma; ±1 mm from midline). A 30-gauge needle attached to a 10 µl Hamilton syringe was aligned over the burr holes and then lowered into the cortex (1 mm ventrally from the base of the skull). Injection of 2 µl of concentrated vector was performed using an automated microinjector (Stoelting, Wood Land, IL, USA) over 5 min. Once vector delivery was completed, the injection needle was slowly extracted (1 mm/min) over a 3-min span. Following surgery, the incision was closed with nylon sutures and the animals were allowed to recover on a heated pad before being returned to their cages. On the indicated days, rapamycin (1 mg/kg; diluted with saline to 1 mg/ml immediately before use, as described previously) was administered by intraperitoneal (i.p.) injection. A total of 20 animals per treatment group were injected in this manner, with 5 additional mice bearing saline-only injections, which served as negative controls. Different groups of mice were subsequently imaged, as described below, at multiple time points to create a composite profile of transgene expression.
Immunohistochemistry
Three days after surgery, the injected mice were deeply anesthetized, as described previously, and fixed by perfusion with 4% PFA. The perfused animals were maintained for 4 h at 4 • C before extracting the brains into 4% PFA overnight. On the following day, the brains were transferred into cryoprotectant (20% sucrose/4% PFA) at 4 • C until equilibrated. The brains were then frozen on dry ice and transferred to a freezer at −80 • C for storage. Thirty-micron sections through the injection site were obtained using a Leica CM3000 cyrostat (Bannockburn, IL, USA), and mounted onto slides. The sections were then processed for GFP expression by immunohistochemistry. Each sample was blocked for non-specific binding with 10% donkey serum (Vector Laboratory, Burlington, CA, USA)/0.4% Triton X-100/phosphate-buffered saline (PBS) for 1 h at room temperature. The sections were then incubated with rabbit anti-GFP primary antibodies (Molecular Probes; 1 : 1000) in blocking solution for 1 h at room temperature. Following three 5-min washes in PBS, the sections were incubated with donkey anti-rabbitAlexa488 (Molecular Probes; 1 : 1000) for 1 h at room temperature to amplify the eGFP signal. The slides were washed again as described and allowed to dry overnight. On the following day, sections were coverslipped using anti-fade mounting reagent containing DAPI (Vector).
Bioluminescence imaging
Luciferase activity in the mouse brain was measured using a cryogenically cooled high efficiency CCD camera system (Roper Scientific, Tucson, AZ, USA). Prior to imaging, animals were anesthetized as described previously and injected i.p. with 150 µg/g body weight D-luciferin (Biosynth International) in standard PBS for 10 min. A light image of the animal was taken using dim polychromatic illumination. The spatial distribution of Fluc activity in the animal was then measured by recording photon counts in the CCD with no illumination. Following data acquisition, post-processing and visualization was performed using an in-house program CMIR-Image, with image display and analysis developed in IDL (Research Systems Inc., Boulder, CO, USA). Each signal was defined using an automated intensity contour procedure to identify bioluminescence signals with intensities significantly greater than background. For visualization purposes, the bioluminescence images were overlaid with the corresponding light images to permit localization of bioluminescence to each animal.
Results
An HSV amplicon plasmid, pHSv.IGiL, was constructed as described in Materials and methods ( Figure 1 ). This vector differs from the previously described HSVbased dimerizer system [9] in four important ways. First, an improved transactivation cassette from ARIAD (Cambridge, MA, USA), which was reported to increase the therapeutic window in RV vectors [10] , was used in these experiments. This improved transactivation cassette contains a more potent version of the NFκB p65 subunit, which consists of a larger portion of the p65 activation domain fused to the activation domain from heat shock factor 1. Second, the fluorescent dsRed cDNA marker was replaced with the bioluminescent Fluc cDNA for imaging expression. Third, the Fluc expression cassette was placed between chicken β-globin insulator elements in an orientation anti-sense to the directionality of the insulator elements [11] to minimize or eliminate basal expression levels. Last, in an attempt to enhance the identification of transduced cells, the woodchuck hepatitis post-transcriptional regulatory element (WPRE) [12] was incorporated immediately downstream of the eGFP cDNA. This improved vector was characterized using human glioblastoma Gli36 cells, which are approximately ten times more infectable than 293T/17 cells. Cells were infected (MOI of 0.1 t.u./cell) for 24 h resulting in 95-99% transduced cells (eGFP + ) (Figures 2A and 2D ).
In the absence of rapamycin (rap) no immunoreactivity for Fluc was detected, indicating that the insulated, inducible promoter had very-little-to-no basal activity ( Figures 2B and 2C ). The addition of 200 nM rap, a dose previously reported to induce gene expression maximally, resulted in many, but not all, of the eGFP-positive cells expressing immunoreactvity for Fluc (red) (Figures 2E  and 2F ). Although control infected, non-induced cells showed no apparent basal level of luciferase expression by immunofluorescence, this assay is not quantitative, nor does it possess the sensitivity necessary for determination of baseline activity. To quickly and accurately measure Fluc activity, a dose-response curve was generated with increasing concentrations of rap (0.2 fM to 200 nM; N = 3 wells/dose) and assayed using a luminometer. No significant changes in Fluc activity were measured between non-infected cells alone and infected, noninduced cells (5 × 10 5 cells/well; data not shown) indicating that Fluc expression was not significant or activated at levels undetectable by the luminometer. As the concentration of rap was increased, doses up to 0.2 nM also did not result in any significant change in Fluc activity. However, at 2 nM rap, significant log-order range of induction, one-log higher than the previous amplicon vector and with no baseline activity ( Figure 3A) . The dose-response curve generated was confirmed by Western blot analysis from infected Gli36 cells ( Figure 3B ). Fluc-immunoreactive bands showed increasing intensity from 2 to 200 nM rap, with no immunoreactive bands detected from doses of 0.2 pM and lower ( Figure 3C ; lower doses not shown). By densitometric analysis of these bands, cells treated at 2 nM 
(B) Baseline image of Fluc-expressing cells in non-induced, untreated samples detected by immunocytochemistry. (E) Fluc-immunoreactive cells 24 h after the addition of rapamycin. (C, F) Merged images to demonstrate infected and induced cells. Total magnification: 10×
induction, the expression of Fluc-immunoreactive bands was significantly less than when compared to a hybrid CMV-enhancer/chicken β-actin promoter (CBA) 48 h post-infection. Immunoblotting against β-tubulin confirmed equivalent sample loading for Fluc expression comparison for HSv.IGiL(a)-infected cells and reduced sample loading for HCBAIG(W)luc3, as expected.
To evaluate the sensitivity of the bioluminescence imaging system with the luminometer, cells were infected at an MOI of 0.1, induced, as described above, and live cells imaged for Fluc activity ( Figure 4A ). The bioluminescence imaging system was evaluated to measure Fluc changes in a rap dose-dependent manner. Cells were infected with HSv.IGiL(a) and treated without or with increasing concentrations of rap ( Figure 4A ). In the absence of rap, no Fluc activity was detected in infected cells. As rap concentration was increased, a dose-response profile was generated. Fluc activity over a range of rap concentrations was then determined. The resulting bioluminescence images were then plotted as mean intensities ( Figure 4B ). Fluc expression from the inducible promoter was about 50% less, when compared to HCBAIG(W)luc3. Attempts to reveal signal at lower doses (e.g., at 200 pM) by increasing collection times resulted in signal expansion from positive samples into neighboring wells. However, the results from this set of experiments do confirm the utility of live imaging for semi-quantitative analysis of Fluc activity.
The sensitive, live imaging analysis of Fluc activity in cells indicated the possibility of imaging Fluc activity directly in the brain. By taking advantage of the neurotropic nature of HSV amplicon vectors, infecting primarily neurons, the ability of HSv.IGiL(a) to induce luciferase expression after induction with rap was then examined in nude mice. HSv.IGiL(a)-mediated gene induction was examined following stereotactic injection of vector (2 µl; 1 × 10 8 t.u./ml) into the cortex. For animal studies, HRG.Luc3, an amplicon expressing Fluc from the CMV promoter, was used instead of HCBAIG(W)luc3 to ensure a measurable signal. Pilot experiments had shown that delivery of HRG.luc3 resulted in robust Fluc signal in the mouse brain (unpublished data), whereas HCBAIG(W)luc3 had not yet been tested. After vector administration, the mice were allowed to recover for 2 days. A baseline image was then taken 48 h after injection to document basal Fluc activity in these animals. Mice injected with HSv.IGiL(a) did not express any Fluc activity ( Figure 5A ), while, as expected, mice receiving injections of the same amounts of HRG.luc3 were already positive for Fluc expression ( Figure 5E ). On the following days, the animals were given a single dose of rap (1 mg/kg) each over 2 days to activate Fluc expression. A second series of images were acquired 2 days after the last rap injection and, as expected, HSv.IGiL(a)-injected brains became Fluc-positive ( Figure 5B ). When compared to HRG.luc3-injected animals ( Figure 5F ), Fluc activity from the inducible cassette was significantly less robust. Both sets of mice were then recovered for 1 week to allow degradation of the induced Fluc protein and re-imaged for Fluc activity. At this time point, HSv.IGiL(a)-treated animals appeared to have lost all Fluc activity ( Figure 5C ). Similarly, HRG.Luc3-injected animals showed a significant decrease in Fluc activity, 13 days after the initial injection ( Figure 5G ). Following the same induction paradigm as described earlier, Fluc activity in the HSv.IGiL(a)-treated mice could not be re-induced ( Figure 5D ) 17 days after vector injection. In addition, mice treated with HRG.luc3 had also lost detectable Fluc activity ( Figure 5H ).
Discussion
These studies have characterized the induced expression of Fluc mediated by a single HSV amplicon vector containing the dimerizer regulatory elements from an imaging perspective. This improved high-capacity, selfcontained amplicon vector is functional in culture and is useful for assessing protein expression profiles in live animals. Although the HSV amplicon vector system is well suited for incorporating genetic elements up to 150 kb [6] , the amplicon vector used did not maximize vector capacity, but still remained of sufficient size (∼15 kb of transgene payload) to demonstrate its capacity over RV, LV, recombinant adenovirus and AAV vectors, with respect to transgene capacity. When packaged into infectious particles, this amplicon genome should contain 7 intact copies of both GFP and Fluc cDNA per virion particle and with Fluc expressed in a drug-responsive manner. Given the multiple copies delivered per virion and the potential for multiple virion infections per cell it was interesting to note that not every infected cell was immunoreactive for Fluc and that the apparent fraction of induced cells as measured by immunocytochemistry was comparable to results published previously [9] , about one-third. This suggests that when characterizing and assessing new therapies in different cell lines, induction, and perhaps expression, of transgenes may be affected by copy number, cell cycle state, intercellular variability and/or limitations in histological assays. Previously, Rivera et al. [17] showed that intramuscular injections of Ad expressing hGH resulted in comparable levels of hGH between the CMV promoter and the fully induced dimerizer system. The results in the present study showed that, in culture, Fluc expression from HSv.IGiL(a) resulted in maximal luciferase activity that was significantly less than that of the CBA promoter (at least 50% by bioluminescence imaging and by Western blot analysis). This contrast between expression levels was unexpected given that induced cells in culture had easy access to rap and were cultured under optimal growth conditions, and suggests that these cells were more responsive to the CBA promoter (or less responsive to the induced, minimal IL2 promoter) or had an unexpected physiologic consequence to rap treatment. In spite of this difference, the cell culture data did indicate that a single administration of rap was sufficient to express transgenes in cultured cells, suggesting that if alternative dosing regimens or cell types were used transgene (Fluc) expression could reach higher levels. This lower level of expression could be beneficial clinically since previous studies have implicated the toxicity of other (over-)expressed marker genes, such as eGFP [18] , in primary neuronal cultures.
The utility of bioluminescence imaging has been well documented, in particular for characterizing antioncogenic therapies [19] . Developing paradigms for monitoring long-term gene expression in culture or in tissues could be of great interest to those interested in assessing the dynamics of long-term protein expression. In these studies, infected, induced cells assessed by the digital analysis of bioluminescence resulted in dose-response curves that were comparable to the dose-response curves generated from the 'gold-standard' measurement of bioluminescence from a luminometer in parallel cultures, with differences reflected by absolute scale. This new non-invasive tool provides increased flexibility and range when designing experiments to investigate levels and consequences of long-term expression in living cells. By adjusting photon collection parameters and virus input, a range of expression can be measured in real time without the need to harvest cells; and under sterile conditions could be monitored repeatedly for protein expression.
Studies using the rapamycin-based promoter system in other viral vectors have indicated the capacity for re-induction of transgenes over several months, and now years [20] , and it was expected that HSv.IGiL(a) could do the same. By applying bioluminescence imaging to the analysis, rapid determination of protein induction/expression was easily achieved. Bioluminescence imaging of a mouse injected with a standard HSV amplicon vector expressing Fluc into its cortex reflects a typical time course for CMV-driven expression, starting after 48 h post-infection and lasting about 2 weeks. Induction of Fluc expression in the inducible vector was also easily measured, with an undetectable off-state prior to rap induction. At 6 days post-injection, CMV-driven expression was quite robust when compared to the maximal induction from the inducible promoter indicating that, for broad-based comparisons, relative amounts of Fluc expression might be comparable (e.g., when comparing different promoter systems).
One of the challenges facing this new technology will be quantifying the exact levels of expression. To achieve significant levels of precision, identical injections must be performed between sets of animals. This is a direct consequence of the physical properties of light. For a positive signal to be measured, photons must escape the transduced tissue area and reach an electronic photon collector. Slight differences in injection location, including the depth of injection, could have profound effects on the ability to collect the total number of photons and enable accurate data analysis. It might be possible to co-deliver a radiolabeled tracer, such as technetium, or far-red-shifted biotinylated quantum dots with the vector to serve as an internal control for delivery depth and location, and provide a means for normalization, still non-invasively.
Given these potential barriers to quantitative analysis of protein expression, it was encouraging to detect robust CMV-driven Fluc expression in the brain, most likely from transduced neurons [5, 8] . However, re-induction of Fluc activity was not achieved following injection of the dimerizer amplicon and it is unclear if this result was vector-or delivery-related. The addition of insulator elements to flank the inducible cassette in the vector did not appear to provide a selective advantage for protein re-induction at later time points, although it is possible that, in its absence, leaky expression in the off-state could have occurred. Work is ongoing to manipulate the vector for maximizing gene expression (e.g., by incorporating a WPRE sequence after the Fluc cDNA or by testing different rap administration paradigms), but the signal loss observed in these studies could have easily been a consequence of vector state after delivery. It is possible that loss of transgene expression can be attributed to the vector remaining extrachromosomal and the promoters becoming quiescent. Use of integrating vectors (HSV/AAV, sleeping beauty, phageC31) [21] [22] [23] could be one possible solution for extending transgene expression. One technical limitation to these studies is the difficulty in generating substantial stocks of purified HSV amplicon vector, making side-by-side comparisons with other vectors difficult. How the concentrated vector delivered in its unpurified milieu to the targeted cells/site affects long-term gene expression is unknown, but could induce the infected cell to activate stress responses to inhibit transgene expression. These studies indicate that bioluminescence imaging of gene expression is possible with focal delivery paradigms, but will probably be most informative when large regions of interest are studied. It is likely that this new tool will be useful for assessing global gene therapeutics. For example, in the treatment of neuromuscular disorders, it may be possible to quickly assess intracellular spread of molecular medicines when fused to luciferase. With newer types of luciferase being discovered and utilized, including those from copepods, which have the smallest cDNA for luciferases and are active in the extracellular space [24] , many new models will be developed to capitalize on novel molecular medicines.
The dimerizer-based expression system has previously been shown to deliver and generate therapeutic proteins at physiologically relevant levels, but is constrained by size when using AAV-or RV-derived vectors [10, 12] . This high-capacity HSV amplicon vector system can facilitate the testing of not only larger potential therapeutic proteins, but also express multiple proteins in a pulsatile or time-dependent manner. By coupling Fluc (or other imaging-compatible protein) to the protein of interest, induction of the fusion protein can be easily determined non-invasively prior to the analysis of experimental parameters. One potential application would be to (over-)express a protein of interest using a constitutively active promoter, and then at a later time point induce the expression of a potential interacting or therapeutic protein (fused to Fluc or expressed bicistronically) to investigate its cellular and/or molecular consequences. This tightly regulated, single, self-contained inducible HSV amplicon vector system has the potential for a number of future applications. As improvements in bioimaging technology are made, these imaging-friendly amplicon vectors become more useful predictors to determine the precise kinetics of gene expression.
